{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:50:34Z","timestamp":1760061034447,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"vor","delay-in-days":1081,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvascsurg.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular Surgery"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.jvs.2010.02.276","type":"journal-article","created":{"date-parts":[[2010,5,18]],"date-time":"2010-05-18T01:20:50Z","timestamp":1274145650000},"page":"369-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A pilot, prospective evaluation of a direct thrombin inhibitor, bivalirudin (Angiomax), in patients undergoing lower extremity bypass"],"prefix":"10.1016","volume":"52","author":[{"given":"Vikram S.","family":"Kashyap","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul D.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James F.","family":"Bena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timur P.","family":"Sarac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Ouriel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvs.2010.02.276_bib1","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1161\/CIRCULATIONAHA.106.174526","volume":"113","author":"Hirsch","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2010.02.276_bib2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1172\/JCI114723","article-title":"Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors","volume":"86","author":"Weitz","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jvs.2010.02.276_bib3","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S0002-8703(00)90050-4","article-title":"Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb\/IIIa antagonist abciximab","volume":"139","author":"Mascelli","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.jvs.2010.02.276_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/01.CIR.97.3.251","article-title":"Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor","volume":"97","author":"Xiao","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2010.02.276_bib5","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1055\/s-0038-1648515","article-title":"Heparin binding to plasma proteins, an important mechanism for heparin resistance","volume":"67","author":"Young","year":"1992","journal-title":"Thromb Haemost"},{"issue":"6 Suppl","key":"10.1016\/j.jvs.2010.02.276_bib6","doi-asserted-by":"crossref","first-page":"340S","DOI":"10.1378\/chest.08-0677","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"133","author":"Warkentin","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.jvs.2010.02.276_bib7","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0741-5214(99)70203-X","article-title":"The role of heparin-associated antiplatelet antibodies in the outcome of arterial reconstruction","volume":"29","author":"Calaitges","year":"1999","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jvs.2010.02.276_bib8","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199705223362107","article-title":"Management of anticoagulation before and after elective surgery","volume":"336","author":"Kearon","year":"1997","journal-title":"N Engl J Med"},{"issue":"2 Pt 1","key":"10.1016\/j.jvs.2010.02.276_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1051-0443(07)61459-6","article-title":"Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: review of the clinical literature","volume":"11","author":"Semba","year":"2000","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jvs.2010.02.276_bib10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/17425250902845646","article-title":"Pharmacological and clinical profile of bivalirudin in the treatment of patients with acute coronary syndrome","volume":"5","author":"White","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jvs.2010.02.276_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","article-title":"Thrombolysis in Myocardial Infarction (TIMI) Trial\u2013phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase","volume":"11","author":"Rao","year":"1988","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jvs.2010.02.276_bib12","doi-asserted-by":"crossref","first-page":"12P","DOI":"10.1016\/S0002-9149(98)00660-2","article-title":"Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin","volume":"82","author":"Bates","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jvs.2010.02.276_bib13","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/eurheartj\/ehp186","article-title":"Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin","volume":"30","author":"Eslam","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jvs.2010.02.276_bib14","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1067\/mhj.2001.119374","article-title":"Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study","volume":"142","author":"Bittl","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.jvs.2010.02.276_bib15","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jvs.2010.02.276_bib16","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jama.292.6.696","article-title":"Long-term efficacy of bivalirudin and provisional glycoprotein IIb\/IIIa blockade vs heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial","volume":"292","author":"Lincoff","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jvs.2010.02.276_bib17","first-page":"651","article-title":"The Angiomax Peripheral Procedure Registry of Vascular Events Trial (APPROVE): in-hospital and 30-day results","volume":"16","author":"Allie","year":"2004","journal-title":"J Invasive Cardiol"},{"key":"10.1016\/j.jvs.2010.02.276_bib18","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jtcvs.2005.10.049","article-title":"Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study","volume":"131","author":"Smedira","year":"2006","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jvs.2010.02.276_bib19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jtcvs.2005.09.057","article-title":"A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study","volume":"131","author":"Dyke","year":"2006","journal-title":"J Thorac Cardiovasc Surg"}],"container-title":["Journal of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521410006610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521410006610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T20:16:54Z","timestamp":1760041014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0741521410006610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0741521410006610"],"URL":"https:\/\/doi.org\/10.1016\/j.jvs.2010.02.276","relation":{},"ISSN":["0741-5214"],"issn-type":[{"type":"print","value":"0741-5214"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A pilot, prospective evaluation of a direct thrombin inhibitor, bivalirudin (Angiomax), in patients undergoing lower extremity bypass","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvs.2010.02.276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}